Damage to the heart muscle after a heart attack can leave scar tissue that is very stiff, leading to symptoms of heart failure, like shortness of breath.
That’s what happened to Conrad “Connie” Foltyn, 69, of Stanton Heights after a series of heart attacks starting in 2003, before he retired as a Pittsburgh police officer. Despite a total of six stents placed to open blocked blood vessels, breathing difficulties limited his activity. He had been told his damaged heart was working too hard and changing shape, making it a poor blood pump for his body.
Information on the Parachute trial
Co-principal investigator at Allegheny General Hospital is David Lasorda. For more information about the Parachute trial there, contact Kenneth Rayl at kray@wpahs.org or call 412-359-6860.
Principal investigators at UPMC Presbyterian are Catalin Toma and Marc Simon. Contact for information is Laurie Dennis at papugall@upmc.edu or call 412-647-6210.
For a video on how the Parachute is implanted, go to www.cardiokinetix.com.
Read More
Heart doctors in Pittsburgh are now testing a device that is designed to permanently restore a more normal function for people who have had one of the most damaging types of heart attack, which affects the left side of the heart, the left ventricle. Qualifying for the clinical trial, on Nov. 6, 2014, Mr. Foltyn was the first to receive the implant at Allegheny General Hospital, and he sees a big difference.
“Before I had this put in,” he said, “I couldn’t finish a sentence to talk. I couldn’t walk from the living room to my kitchen, without stopping two or three times. This is a game changer for me.”
The device, called the Parachute, is now being tested at more than 60 locations, including Allegheny General Hospital and UPMC Presbyterian, which are both enrolling patients. Researchers say they want to see if the Parachute can be another option to control symptoms and reduce patients’ risk of hospitalization and death.
Principal investigator in the Allegheny General Hospital arm of the study, cardiologist Srinivas Murali said researchers hope to recruit about 550 patients in the randomized trial. Half will get the experimental device implanted and all participants will get any medicine prescribed for their heart condition. They will be followed for one year to see if the device prevents death or worsening heart failure.
A normal heart pumps a little more than half the heart’s blood volume with each beat. Dr. Murali explained that scarring in the left ventricle reduces that capacity, and the study focuses on patients whose left ventricle is limited to pumping out less than 35 percent of its blood with each heartbeat.
That level of function “increases the risk of life-threatening irregular heartbeats that can cause sudden cardiac arrest and sudden cardiac death,” according to the Cleveland Clinic website. The healthy part of the heart tries to compensate by working harder to pump blood.
“The heart has to have, geometrically, a football shape,” Dr. Murali said. “With damage, the heart starts to remodel. It starts to become more like a soccer ball. … The device prevents the remodeling.”
The Parachute is like a tiny umbrella, with 16 struts and a “parchment-like” material, Dr. Murali said. Inserted with a catheter from the leg artery to the heart, it opens up inside the ventricle and attaches itself to the wall of the heart with anchors at the end of each strut. It partitions off the damaged tissue and decreases the volume inside the ventricle.
Dr. Murali said the Parachute belongs to a category of devices designed to prevent the heart from remodeling after a heart attack, adding that it is approved for this use in Europe. CardioKinetix is the device maker and sponsor of the clinical trial. The implanting procedure is estimated to take 75 minutes and after six months, body tissue covers it.
Made of materials that are compatible with human tissue, Dr. Murali said, “It is able to adapt to the space around it. It conforms to the shape of the individual patient’s heart.”
Even with available devices, such as defibrillators, patients continue to get worse, he said, adding that five years after the heart attack, they often need a heart transplant or LVAD (left ventricular assist device, a mechanical heart pump) to stay alive.
Mr. Foltyn said he jumped at the chance to be part of the Parachute trial.
“You don’t recover from congestive heart failure. … My aunt and brother died from congestive heart failure. Anything that slows this process down, it’s gravy,” he said.
New habits help Mr. Foltyn continue to enjoy his retirement activities, which include working in his yard and building model cars. He’s replaced smoking and alcohol with decaffeinated coffee, a very low-salt diet, moderate amounts of foods with sugar and controlled fluid intake, to reduce any swelling in his hands and feet.
By preventing the remodeling of the heart, Dr. Murali said, researchers hope to delay the need for a transplant or LVAD. If the trial is successful, CardioKinetix can seek approval from the U.S. Food and Drug Administration to market the device.
“It doesn’t eliminate the problem,” Dr. Murali said, “it allows us to manage the patient [so they are] feeling better, have fewer symptoms … continue their activities.”
Jill Daly: jdaly@post-gazette.com, 412-263-1596.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.